In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look into Sanofi (SNY 1.15%) after its earnings report to discuss some of the biggest upcoming drugs in the company's pipeline.
As the company's flagship product, its insulin Lantus, nears the patent cliff, the guys look at the company's Lantus replacement, U300, ahead of its upcoming filing. They also look at Sanofi's PCSK9 drug alirocumab, which would compete directly with Amgen's (AMGN 0.60%) and Pfizer's (PFE 0.23%) offerings in this space, and which should be releasing phase 3 data in late summer or early fall.
